These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24764685)
1. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer. Zong L; Chen P; Wang DX World J Gastroenterol; 2014 Apr; 20(15):4440-5. PubMed ID: 24764685 [TBL] [Abstract][Full Text] [Related]
2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643 [TBL] [Abstract][Full Text] [Related]
3. [Relationship between expression of decoy receptor 3 and apoptosis in hepatocellular carcinoma]. Chen G; Luo DZ; Wang Y; Liao ZL; Zhang MY Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):113-7. PubMed ID: 17493386 [TBL] [Abstract][Full Text] [Related]
4. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Chen G; Luo D Ups J Med Sci; 2008; 113(3):297-304. PubMed ID: 18991242 [TBL] [Abstract][Full Text] [Related]
5. Decoy receptor 3 is a prognostic factor in renal cell cancer. Macher-Goeppinger S; Aulmann S; Wagener N; Funke B; Tagscherer KE; Haferkamp A; Hohenfellner M; Kim S; Autschbach F; Schirmacher P; Roth W Neoplasia; 2008 Oct; 10(10):1049-56. PubMed ID: 18813347 [TBL] [Abstract][Full Text] [Related]
6. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Mild G; Bachmann F; Boulay JL; Glatz K; Laffer U; Lowy A; Metzger U; Reuter J; Terracciano L; Herrmann R; Rochlitz C Int J Cancer; 2002 Nov; 102(3):254-7. PubMed ID: 12397645 [TBL] [Abstract][Full Text] [Related]
7. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. Liang QL; Wang BR; Li GH J Zhejiang Univ Sci B; 2009 Sep; 10(9):675-82. PubMed ID: 19735100 [TBL] [Abstract][Full Text] [Related]
8. DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC. Liu YP; Zhu HF; Liu DL; Hu ZY; Li SN; Kan HP; Wang XY; Li ZG Oncotarget; 2016 Nov; 7(47):77306-77318. PubMed ID: 27764793 [TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580 [TBL] [Abstract][Full Text] [Related]
10. Decoy Receptor 3 Expression Is Associated With Wild-Type EGFR Status, Poor Differentiation of Tumor, and Unfavorable Patient Outcome. Chang WC; Yeh YC; Ho HL; Hsieh SL; Chou TY Am J Clin Pathol; 2019 Jul; 152(2):207-216. PubMed ID: 31077284 [TBL] [Abstract][Full Text] [Related]
11. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. Cho JH; Lim JY; Cho JY World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694 [TBL] [Abstract][Full Text] [Related]
12. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854 [TBL] [Abstract][Full Text] [Related]
13. Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma. Zhou J; Song S; Li D; He S; Zhang B; Wang Z; Zhu X World J Surg Oncol; 2014 Mar; 12():52. PubMed ID: 24597666 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. Huang S; Chen G; Dang Y; Chen LH ScientificWorldJournal; 2014; 2014():605236. PubMed ID: 24741354 [TBL] [Abstract][Full Text] [Related]
15. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. Dang HZ; Yu Y; Jiao SC World J Gastroenterol; 2012 May; 18(19):2402-7. PubMed ID: 22654433 [TBL] [Abstract][Full Text] [Related]
16. Overexpression and clinicopathological contribution of DcR3 in bladder urothelial carcinoma tissues. Jiang YQ; Zhong TF; Dang YW; Zou LS; Yang L; Yang X; Chen G Asian Pac J Cancer Prev; 2014; 15(21):9137-42. PubMed ID: 25422191 [TBL] [Abstract][Full Text] [Related]
17. Decoy Receptor 3 (DcR3) as a Biomarker of Tumor Deterioration in Female Reproductive Cancers: A Meta-Analysis. Jiang M; Lin X; He R; Lin X; Liang L; Tang R; Xiong D; Wei K; Dang Y; Feng Z; Chen G Med Sci Monit; 2016 Jun; 22():1850-7. PubMed ID: 27246752 [TBL] [Abstract][Full Text] [Related]
18. The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma. Weissinger D; Tagscherer KE; Macher-Göppinger S; Haferkamp A; Wagener N; Roth W Mol Cancer; 2013 Oct; 12(1):120. PubMed ID: 24107265 [TBL] [Abstract][Full Text] [Related]
19. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma. Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of expression and amplification of the DcR3 gene in pancreatic carcinomas. Zhou J; Song SD; Li DC; Zhou J; Zhu DM; Zheng SY Asian Pac J Cancer Prev; 2012; 13(2):719-24. PubMed ID: 22524850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]